• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clock gene NR1D1 might be a novel target for the treatment of bladder cancer
CONCLUSION: NR1D1 played a role of tumor suppressor and it might become a novel target for the treatment of BC.PMID:37208228 | DOI:10.1016/j.urolonc.2023.04.021
Source: Urologic Oncology - May 19, 2023 Category: Urology & Nephrology Authors: Yubo Yang Yunjin Bai Xiaoming Wang Yaochuan Guo Zhihai Yu Dechao Feng Facai Zhang Dengxiong Li Ping Han Source Type: research

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
CONCLUSIONS: The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.PMID:34083096 | DOI:10.1016/j.urolonc.2021.04.011
Source: Urologic Oncology - June 4, 2021 Category: Urology & Nephrology Authors: Tilman Todenh öfer Ewan A Gibb Roland Seiler Alireza Kamyabi J örg Hennenlotter Paul McDonald Igor Moskalev Craig Stewart Jian Gao Ladan Fazli Shoukat Dedhar Arnulf Stenzl Htoo Zarni Oo Peter C Black Source Type: research

Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
CONCLUSIONS: These data demonstrate that treatment with ARN-509 leads to increased autophagy levels in LNCaP cells. Furthermore, in combination with autophagy inhibitors, ARN-509 provided a significantly elevated antitumor effect, thus providing a new therapeutic approach potentially translatable to patients. PMID: 32466878 [PubMed - as supplied by publisher]
Source: Urologic Oncology - May 24, 2020 Category: Urology & Nephrology Authors: Eberli D, Kranzbühler B, Mortezavi A, Sulser T, Salemi S Tags: Urol Oncol Source Type: research

The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma.
CONCLUSION: DYSF mRNA and protein expression are opposingly involved in tumor progression of ccRCC. DYSF could be used as a prognostic biomarker to predict survival of patients with ccRCC. PMID: 32430251 [PubMed - as supplied by publisher]
Source: Urologic Oncology - May 16, 2020 Category: Urology & Nephrology Authors: Cox A, Zhao C, Tolkach Y, Nettersheim D, Schmidt D, Kristiansen G, Hauser S, Müller SC, Ritter M, Ellinger J Tags: Urol Oncol Source Type: research

RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.
CONCLUSIONS: RPS7 is a newly verified tumor promoter in PCa, and promotes cell migration by targeting epithelial-to-mesenchymal transition pathway. Thus, inhibition of RPS7-epithelial to-mesenchymal transition signaling might represent a prospective approach toward limiting prostate tumor progression. PMID: 30737160 [PubMed - as supplied by publisher]
Source: Urologic Oncology - February 5, 2019 Category: Urology & Nephrology Authors: Wen Y, An Z, Qiao B, Zhang C, Zhang Z Tags: Urol Oncol Source Type: research

Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer☆,☆☆?>
CONCLUSION: These findings suggest that both the mTOR pathway downstream of eukaryotic initiation factor 4E and S6K1 can be successfully inhibited, therefore, the recurrence of bladder cancer can be prevented by high-dose rapamycin only, suggesting that 4E-BP1 might be still under mTORC1. PMID: 24239466 [PubMed - as supplied by publisher]
Source: Urologic Oncology - November 13, 2013 Category: Urology & Nephrology Authors: Kyou Kwon J, Kim SJ, Hoon Kim J, Mee Lee K, Ho Chang I Tags: Urol Oncol Source Type: research

The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
CONCLUSIONS: Our results demonstrate that Vav3 plays a crucial role in prostate cancer growth and malignant behavior, thus revealing a novel potential therapeutic target. PMID: 23403204 [PubMed - as supplied by publisher]
Source: Urologic Oncology - February 8, 2013 Category: Urology & Nephrology Authors: Hirai K, Nomura T, Yamasaki M, Inoue T, Narimatsu T, Chisato Nakada PD, Yoshiyuki Tsukamoto PD, Matsuura K, Sato F, Moriyama M, Mimata H Tags: Urol Oncol Source Type: research